Please login to the form below
hVIVO
This page shows the latest hVIVO news and features for those working in and with pharma, biotech and healthcare.
UK to launch world-first COVID-19 human challenge study in the ‘next few weeks’
collaboration with clinical company hVIVO and with support from virologists at Imperial College London. ... The COVID-19 human challenge study is part of a partnership between the UK’s Vaccines Taskforce, Imperial College London, the Royal Free London
Latest news
-
UK government invests in human challenge trials for COVID-19
The study will be sponsored by Imperial College London and conducted by hVIVO at The Royal Free Hospital’s specialist research unit in London. ... The government has already secured the first three slots to test vaccine using the challenge study, which
-
Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more
UK BIOTECH. Universal flu vaccine shows promise in phase 2. UK next-generation vaccines company hVIVO has unveiled promising results for its universal flu vaccine candidate. ... FLU-v is being developed by Imutex, hVIVO's 49% joint venture with PepTcell
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
